Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/Ib, Open-label, Multiple Ascending Dose, First-in-Human Study, to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of INT-1B3 in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

Phase I/Ib, Open-label, Multiple Ascending Dose, First-in-Human Study, to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of INT-1B3 in Patients With Advanced Solid Tumors

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 09 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs INT 1B3 (Primary)
  • Indications Advanced breast cancer; Liver cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors InteRNA Technologies

Most Recent Events

  • 06 Feb 2024 Status changed from recruiting to discontinued.
  • 02 Dec 2021 According to an InteRNA Technologies media release, the company topline results from the dose escalation ( Phase Ia ) part of the study are expected in the first half of 2022.
  • 02 Dec 2021 According to an InteRNA Technologies media release, the company expects the treatment of the first patient in the dose expansion (Phase Ib) part of the study in the second half of 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top